0.73
+0.0487(+7.14%)
Currency In USD
| Previous Close | 0.68 |
| Open | 0.68 |
| Day High | 0.76 |
| Day Low | 0.68 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 22.08M |
| Average Volume | 22.75M |
| Market Cap | 44.23M |
| PE | -0.53 |
| EPS | -1.39 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 0.73 |
| Change | 0.05 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.02 as of October 04, 2025 at a share price of $0.731. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $18.68 as of October 04, 2025 at a share price of $0.731.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
GlobeNewswire Inc.
Sep 25, 2025 11:30 AM GMT
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insura
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
GlobeNewswire Inc.
Sep 22, 2025 11:30 AM GMT
Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
GlobeNewswire Inc.
Sep 18, 2025 11:30 AM GMT
Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Im